The management of RAML has changed over the years: while early treatment was nephrectomy, later a more conservative approach utilizing embolization and nephron sparing surgery (NSS), and finally the mammalian target of rapamycin (mTOR) inhibitors has been proved effective to halt and reverse TSC-associated RAML (TSC-RAML) (2, 3). Here, MTOR is linked to kidney angiomyolipoma.